Clinical Trial Update: ALADDIN Study: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation [Phase 2]

View source ↗

Summary

The ALADDIN Phase 2 trial evaluating leuprolide as an antigonadotropin for Alzheimer's disease has completed. The sponsor is Voyager Pharmaceutical Corporation …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Leuprolide (Leuprolide acetate)

Snippet

Sponsor: Voyager Pharmaceutical Corporation | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED